Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Abstract
No abstract available
Funding Information
  • Pfizer
  • AstraZeneca
  • Pfizer
  • AstraZeneca
  • Chugai
  • Eli Lilly
  • GSK
  • Daiichi-Sankyo
  • Pfizer
  • Novartis
  • Pfizer
  • US Department of Defense Breast Cancer Innovator Award
  • Revlon/University of California, Los Angeles Women's Cancer Research Program
  • Peter and Denise Wittich Breast Cancer Program

This publication has 32 references indexed in Scilit: